Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
.jpg)
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ilaris (canakinumab) is a monoclonal antibody that blocks interleukin-1 beta (IL-1β), a key driver of inflammation in several rare periodic fever syndromes and inflammatory conditions.
Ilaris is FDA-approved for Cryopyrin-Associated Periodic Syndromes (CAPS), TNF Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency, and Familial Mediterranean Fever (FMF) in adult and pediatric patients. It is also approved for active Still's disease — both Adult-Onset Still's Disease and Systemic Juvenile Idiopathic Arthritis — in patients 2 years and older, and for symptomatic treatment of gout flares in adults when NSAIDs, colchicine, and repeated corticosteroids are not appropriate options.
Canakinumab selectively binds to and neutralizes IL-1β, blocking its interaction with IL-1 receptors and reducing the inflammatory cascade that drives symptoms in these conditions.
Dosing varies by indication: for periodic fever syndromes and Still's disease, the typical dose is 150 mg (or weight-based for pediatric patients) subcutaneously every 4 weeks, sometimes increased to 300 mg if response is inadequate. For gout flares, a single 150 mg subcutaneous dose is given as early as possible after symptom onset, as determined by the treating specialist.
Ilaris requires monitoring for several important safety considerations, particularly related to infection risk.
Ilaris increases the risk of serious infections, including unusual or opportunistic infections such as aspergillosis, atypical mycobacterial infections, cytomegalovirus, and herpes zoster. Do not initiate treatment during an active infection, and discontinue if a serious infection develops.
The most common adverse event, occurring in about 1 in 10 patients.
A known risk in Still's disease patients; monitor closely for signs and symptoms.
Live vaccines should not be given concurrently with Ilaris. Patients should be brought up to date with recommended vaccinations before starting treatment.
Long-term effects on the immune system, including malignancy risk, are not fully known; monitor patients accordingly.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Ilaris (canakinumab) is manufactured by Novartis and is approved across multiple rare periodic fever syndromes, Still's disease, and gout flares.
Import of Ilaris through a Named Patient Program requires a valid prescription from the treating rheumatologist or specialist, diagnosis confirmation, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Ilaris directly from Novartis's authorized supply chain to ensure product authenticity and regulatory compliance.
Ilaris is sourced through verified, GDP-compliant, cold-chain channels from Novartis's authorized supply chain to ensure authenticity and quality.
Ilaris should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Ilaris is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Ilaris through NPP's regulated import pathway, with rheumatology and immunology specialists in major cities supporting the treatment process.
Leading rheumatology centers in Mumbai support diagnosis and treatment coordination for Ilaris access.
Delhi's major hospitals assist patients with diagnostic confirmation and prescription support for Ilaris.
Bangalore's specialist network offers access to Ilaris for eligible patients with rare periodic fever syndromes and Still's disease.
Chennai-based specialists coordinate Ilaris access alongside comprehensive rheumatologic care.
Hyderabad's care institutions support patients pursuing Ilaris therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Ilaris.
Pune-based specialists assist with diagnosis confirmation and Ilaris treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Ilaris.
Kochi's specialist units assist patients with the documentation needed for Ilaris access.
Chandigarh's care centers support Ilaris treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Ilaris access process.
Lucknow-based centers assist patients pursuing Ilaris therapy.
Bhubaneswar's institutions support access to Ilaris for eligible patients.
Guwahati's specialists help coordinate Ilaris access for patients across the Northeast.
Patients in other cities across India can also access Ilaris through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
